SEATTLE CHILDREN’S signed a letter of intent with Juno Therapeutics Inc. to expand their collaboration to accelerate the availability of T-cell immunotherapy clinical trials for children and adults with brain tumors. The aim of the collaboration is to fast-track clinical implementation with the goal of opening phase I clinical trials within the next two years....
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
